| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:52 UTC |
|---|
| Update Date | 2020-02-26 21:42:01 UTC |
|---|
| HMDB ID | HMDB0015666 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Lornoxicam |
|---|
| Description | Lornoxicam, also known as XEFO or acabel, belongs to the class of organic compounds known as thienothiazines. These are heterocyclic compounds containing a thiophene ring fused to a thiazine. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Thiazine is a 6-membered ring consisting of four carbon, one nitrogen and one sulfur atoms. Lornoxicam is a strong basic compound (based on its pKa). In humans, lornoxicam is involved in lornoxicam action pathway. Lornoxicam is approved for use in Japan. Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. |
|---|
| Structure | CN1\C(=C(\O)NC2=CC=CC=N2)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,19H,1H3,(H,15,16)/b13-10+ |
|---|
| Synonyms | | Value | Source |
|---|
| Acabel | HMDB | | Chlortenoxicam | HMDB | | CLTX | HMDB | | Lorcam | HMDB | | Lornoxicamum | HMDB | | Safem | HMDB | | Taigalor | HMDB | | Telos | HMDB | | XEFO | HMDB | | Xefocam | HMDB |
|
|---|
| Chemical Formula | C13H10ClN3O4S2 |
|---|
| Average Molecular Weight | 371.819 |
|---|
| Monoisotopic Molecular Weight | 370.98012491 |
|---|
| IUPAC Name | (3E)-6-chloro-3-{hydroxy[(pyridin-2-yl)amino]methylidene}-2-methyl-2H,3H,4H-1λ⁶-thieno[2,3-e][1,2]thiazine-1,1,4-trione |
|---|
| Traditional Name | telos |
|---|
| CAS Registry Number | 70374-39-9 |
|---|
| SMILES | CN1\C(=C(\O)NC2=CC=CC=N2)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O |
|---|
| InChI Identifier | InChI=1S/C13H10ClN3O4S2/c1-17-10(13(19)16-9-4-2-3-5-15-9)11(18)12-7(23(17,20)21)6-8(14)22-12/h2-6,19H,1H3,(H,15,16)/b13-10+ |
|---|
| InChI Key | OXROWJKCGCOJDO-JLHYYAGUSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as thienothiazines. These are heterocyclic compounds containing a thiophene ring fused to a thiazine. Thiophene is 5-membered ring consisting of four carbon atoms and one sulfur atom. Thiazine is a 6-membered ring consisting of four carbon, one nitrogen and one sulfur atoms. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Thienothiazines |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Thienothiazines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Thienothiazine
- 2,3,5-trisubstituted thiophene
- Aryl ketone
- Secondary aliphatic/aromatic amine
- Ortho-thiazine
- Aryl chloride
- Aryl halide
- Pyridine
- Organosulfonic acid amide
- Imidolactam
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Heteroaromatic compound
- Thiophene
- Vinylogous amide
- Vinylogous acid
- Ketone
- Secondary amine
- Alkanolamine
- Azacycle
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Amine
- Organic oxygen compound
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | Not Available |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | 2.62 | BIOBYTE STARLIST (2009) |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.78 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 14.4026 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.91 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 31.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2596.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 364.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 120.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 217.7 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 140.1 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 517.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 805.1 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 217.0 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1098.0 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 392.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1740.1 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 383.7 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 404.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 640.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 223.3 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 160.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Lornoxicam,1TMS,isomer #1 | CN1/C(=C(\NC2=CC=CC=N2)O[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 3067.3 | Semi standard non polar | 33892256 | | Lornoxicam,1TMS,isomer #2 | CN1/C(=C(/O)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 3021.8 | Semi standard non polar | 33892256 | | Lornoxicam,2TMS,isomer #1 | CN1/C(=C(/O[Si](C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 2970.5 | Semi standard non polar | 33892256 | | Lornoxicam,2TMS,isomer #1 | CN1/C(=C(/O[Si](C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 3196.7 | Standard non polar | 33892256 | | Lornoxicam,2TMS,isomer #1 | CN1/C(=C(/O[Si](C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 4057.1 | Standard polar | 33892256 | | Lornoxicam,1TBDMS,isomer #1 | CN1/C(=C(\NC2=CC=CC=N2)O[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 3271.7 | Semi standard non polar | 33892256 | | Lornoxicam,1TBDMS,isomer #2 | CN1/C(=C(/O)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 3248.8 | Semi standard non polar | 33892256 | | Lornoxicam,2TBDMS,isomer #1 | CN1/C(=C(/O[Si](C)(C)C(C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 3310.4 | Semi standard non polar | 33892256 | | Lornoxicam,2TBDMS,isomer #1 | CN1/C(=C(/O[Si](C)(C)C(C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 3673.8 | Standard non polar | 33892256 | | Lornoxicam,2TBDMS,isomer #1 | CN1/C(=C(/O[Si](C)(C)C(C)(C)C)N(C2=CC=CC=N2)[Si](C)(C)C(C)(C)C)C(=O)C2=C(C=C(Cl)S2)S1(=O)=O | 4063.3 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Lornoxicam GC-MS (Non-derivatized) - 70eV, Positive | splash10-0006-5921000000-6f9ae5cf4b1b0097a406 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Lornoxicam GC-MS (1 TMS) - 70eV, Positive | splash10-006y-7491100000-cfd19c2004e4ef1f72fd | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Lornoxicam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Lornoxicam GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 10V, Positive-QTOF | splash10-00dj-6039000000-5acd8e014a66cfeba274 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 20V, Positive-QTOF | splash10-0002-9200000000-79cac3b848eaf37323a4 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 40V, Positive-QTOF | splash10-0002-9800000000-666e04068ab04bb09533 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 10V, Negative-QTOF | splash10-014i-3049000000-fd314afee7bb217013f7 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 20V, Negative-QTOF | splash10-0006-8900000000-559e35dd6fe4470b2b78 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 40V, Negative-QTOF | splash10-0089-3900000000-1e73e6eb2363580b2ef2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 10V, Positive-QTOF | splash10-00di-1009000000-ace9fdbf0f3a5ca12dc9 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 20V, Positive-QTOF | splash10-00dj-8439000000-3d1eb3b1155415f02002 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 40V, Positive-QTOF | splash10-004i-9100000000-81f13509aa816da18f32 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 10V, Negative-QTOF | splash10-014i-0019000000-5ccae5802952cfdead8b | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 20V, Negative-QTOF | splash10-0002-1192000000-9f2aef1c184c6a8f77e0 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lornoxicam 40V, Negative-QTOF | splash10-0006-9122000000-790da4b14580b297d68a | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Bonnabry P, Leemann T, Dayer P: Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol. 1996;49(4):305-8. [PubMed:8857077 ]
- Pruss TP, Stroissnig H, Radhofer-Welte S, Wendtlandt W, Mehdi N, Takacs F, Fellier H: Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J. 1990;66 Suppl 4:S18-21. [PubMed:2284216 ]
- Hitzenberger G, Radhofer-Welte S, Takacs F, Rosenow D: Pharmacokinetics of lornoxicam in man. Postgrad Med J. 1990;66 Suppl 4:S22-7. [PubMed:2284217 ]
- Olkkola KT, Brunetto AV, Mattila MJ: Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet. 1994 Feb;26(2):107-20. [PubMed:8162655 ]
- Vane JR: Introduction: mechanism of action of NSAIDs. Br J Rheumatol. 1996 Apr;35 Suppl 1:1-3. [PubMed:8630629 ]
- Balfour JA, Fitton A, Barradell LB: Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs. 1996 Apr;51(4):639-57. [PubMed:8706598 ]
- Skjodt NM, Davies NM: Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. Clin Pharmacokinet. 1998 Jun;34(6):421-8. [PubMed:9646006 ]
- Radhofer-Welte S, Rabasseda X: Lornoxicam, a new potent NSAID with an improved tolerability profile. Drugs Today (Barc). 2000 Jan;36(1):55-76. [PubMed:12879104 ]
|
|---|